- Home
- MRNA vs SSNC Comparison
MRNA vs SSNC Comparison
Compare MRNA & SSNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- SSNC
- Stock Information
- Founded
- MRNA 2010
- SSNC 1986
- Country
- MRNA United States
- SSNC United States
- Employees
- MRNA N/A
- SSNC N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- SSNC EDP Services
- Sector
- MRNA Health Care
- SSNC Technology
- Exchange
- MRNA Nasdaq
- SSNC Nasdaq
- Market Cap
- MRNA 16.5B
- SSNC 18.9B
- IPO Year
- MRNA 2018
- SSNC 1996
- Fundamental
- Price
- MRNA $38.36
- SSNC $73.65
- Analyst Decision
- MRNA Hold
- SSNC Strong Buy
- Analyst Count
- MRNA 19
- SSNC 8
- Target Price
- MRNA $79.50
- SSNC $77.75
- AVG Volume (30 Days)
- MRNA 7.7M
- SSNC 1.2M
- Earning Date
- MRNA 11-07-2024
- SSNC 02-11-2025
- Dividend Yield
- MRNA N/A
- SSNC 1.29%
- EPS Growth
- MRNA N/A
- SSNC 15.08
- EPS
- MRNA N/A
- SSNC 2.79
- Revenue
- MRNA $5,081,000,000.00
- SSNC $5,763,900,000.00
- Revenue This Year
- MRNA N/A
- SSNC $8.22
- Revenue Next Year
- MRNA N/A
- SSNC $5.58
- P/E Ratio
- MRNA N/A
- SSNC $27.24
- Revenue Growth
- MRNA N/A
- SSNC 6.16
- 52 Week Low
- MRNA $35.80
- SSNC $58.79
- 52 Week High
- MRNA $170.47
- SSNC $77.69
- Technical
- Relative Strength Index (RSI)
- MRNA 35.63
- SSNC 38.25
- Support Level
- MRNA $41.06
- SSNC $75.68
- Resistance Level
- MRNA $44.38
- SSNC $77.67
- Average True Range (ATR)
- MRNA 2.57
- SSNC 1.09
- MACD
- MRNA 0.16
- SSNC -0.31
- Stochastic Oscillator
- MRNA 1.74
- SSNC 0.00
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About SSNC SS&C Technologies Holdings Inc.
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual data room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.